BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

...Swiss biotech Orphan Technologies Ltd. The candidate, OT-58...
BioCentury | Sep 17, 2020
Deals

Awaiting dialogue with FDA on GI program, microbiome play Finch looks to autism, HBV with new $90M round

...that Smith said can induce production of oxytocin...
BioCentury | Aug 8, 2020
Translation in Brief

Cocrystal’s COVID-19 antivirals; plus a portable breast cancer diagnostic, Tarveda mini-drug conjugate for solid tumors, and more

...autistic behaviors caused by an autism-associated NLGN3 mutation. In mice, the mutation led to impaired oxytocin...
...tegmental area, a brain region that contributes to the behavioral responses. The MKNK1/2 inhibitor restored oxytocin-induced...
...HER2) (EGFR2) (ErbB2) (neu) Estrogen receptor 1 (ER) (ESR1) Estrogen receptor 2 (ESR2) Progesterone receptor (PR) (PGR) Neuroligin 3 (NLGN3) Oxytocin (OXT) (OT) MAP...
BioCentury | Dec 17, 2019

ELK1 overexpression for Huntington disease

...that are dysregulated in HD and have been implicated in disease pathogenesis, including oxytocin (OXT; OT...
BioCentury | Sep 28, 2019
Politics & Policy

Congress clears CDER reorganization aimed at deepening FDA therapeutic expertise

Congress has signed off on an FDA reorganization that is intended to allow drug reviewers to develop greater expertise in both the diseases that are being treated and the technologies underlying new medicines. The changes...
BioCentury | Sep 19, 2019
Distillery Therapeutics

Blocking the NAD+ biosynthesis enzyme NamPRT for PPM1D-mutant tumors

...penetrate the CNS and developing alternate CNS delivery mechanisms. OncoTartis Inc. has a NamPRT inhibitor, OT-82...
BioCentury | Sep 12, 2019
Distillery Therapeutics

CDK11B as a new cancer target

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer; pancreatic cancer; breast cancer Inhibiting CDK11B, a kinase involved in cellular processes including transcription and chromosome segregation, could treat cancers including colorectal, pancreatic, lung cancer and melanoma. In colorectal...
BioCentury | Sep 11, 2019
Translation in Brief

Cold Spring Harbor team finds off-target activity can drive antitumor effects

Drug developers may need to revise how they validate drug targets, according to a Cold Spring Harbor Laboratory study that found 10 clinical oncology candidates killed tumor cells by hitting unintended targets. The study also...
BioCentury | Sep 11, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

...a U.S. Phase III trial expected in 2020. Mateon taps WideTrial for expanded access to OT-101...
...Inc. (OTCQB:MATN) partnered with WideTrial Inc. (San Francisco, Calif.) to provide expanded access to Mateon’s OT-101...
...inclusion criteria of trials of the therapy. The deal also may support expanded access to OT-101...
BioCentury | Aug 10, 2018
Finance

Missing the obvious

...surgery, which could have a huge impact on women’s lives. ObsEva’s recent success with the oxytocin...
Items per page:
1 - 10 of 108